Abstract
Overexpression and/or gene amplification of c-Src and members of the epidermal growth factor receptor (EGFR/ErbB) family have been implicated in the pathogenesis of breast cancer. Although members of the EGFR family are known to form heterocomplexes with one another, c-Src has also been shown to physically interact with members of this family in breast cancer cell lines and tumors. This paper investigates the role of c-Src in modulating the physical and functional interaction between ErbB2 and ErbB3, two family members that preferentially associate with one another and together exhibit high oncogenic potential. We show that overexpressed wild-type c-Src enhances heterocomplex formation of ErbB2 and ErbB3 that results in increased basal and/or heregulin-induced activation of receptors, and their downstream intracellular effectors. Expression of a kinase-inactive form of c-Src (K− c-Src) or pharmacological inhibition of c-Src by PP2 negatively affects these events. Furthermore, cellular motility and anchorage-independent growth promoted by the ErbB2/ErbB3 heterocomplex are dependent upon c-Src, as demonstrated by the effects of K− c-Src overexpression or treatment with PP2. In contrast to previous studies that defined a role for c-Src downstream of ErbB2/ErbB3, the current work suggests an upstream mechanism, whereby c-Src enhances ErbB2/ErbB3 signaling and biological functions by positively modulating the association between ErbB2 and ErbB3.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Abu-Ghazaleh R, Kabir J, Jia H, Lobo M, Zachary I . (2001). Src mediates stimulation by vascular endothelial growth factor of the phosphorylation of focal adhesion kinase at tyrosine 861, and migration and anti-apoptosis in endothelial cells. Biochem J 360: 255–264.
Akiyama T, Matsuda S, Namba Y, Saito T, Toyoshima K, Yamamoto T . (1991). The transforming potential of the c-erbB-2 protein is regulated by its autophosphorylation at the carboxyl-terminal domain. Mol Cell Biol 11: 833–842.
Bao J, Gur G, Yarden Y . (2003). Src promotes destruction of c-Cbl: implications for oncogenic synergy between Src and growth factor receptors. Proc Natl Acad Sci USA 100: 2438–2443.
Belsches-Jablonski AP, Biscardi JS, Peavy DR, Tice DA, Romney DA, Parsons SJ . (2001). Src family kinases and HER2 interactions in human breast cancer cell growth and survival. Oncogene 20: 1465–1475.
Biscardi JS, Maa MC, Tice DA, Cox ME, Leu TH, Parsons SJ . (1999). c-Src-mediated phosphorylation of the epidermal growth factor receptor on Tyr845 and Tyr1101 is associated with modulation of receptor function. J Biol Chem 274: 8335–8343.
Di Fiore PP, Pierce JH, Kraus MH, Segatto O, King CR, Aaronson SA . (1987b). erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science 237: 178–182.
Fan YX, Wong L, Deb TB, Johnson GR . (2004). Ligand regulates epidermal growth factor receptor kinase specificity: activation increases preference for GAB1 and SHC versus autophosphorylation sites. J Biol Chem 279: 38143–38150.
Holbro T, Beerli RR, Maurer F, Koziczak M, Barbas III CF, Hynes NE . (2003). The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci USA 100: 8933–8938.
Ishizawar R, Parsons SJ . (2004). c-Src and cooperating partners in human cancer. Cancer Cell 6: 209–214.
Kanner SB, Reynolds AB, Vines RR, Parsons JT . (1990). Monoclonal antibodies to individual tyrosine-phosphorylated protein substrates of oncogene-encoded tyrosine kinases. Proc Natl Acad Sci USA 87: 3328–3332.
Kim H, Chan R, Dankort DL, Zuo D, Najoukas M, Park M et al. (2005). The c-Src tyrosine kinase associates with the catalytic domain of ErbB-2: implications for ErbB-2 mediated signaling and transformation. Oncogene 24: 7599–7607.
Luttrell DK, Lee A, Lansing TJ, Crosby RM, Jung KD, Willard D et al. (1994). Involvement of pp60c-src with two major signaling pathways in human breast cancer. Proc Natl Acad Sci USA 91: 83–87.
Muthuswamy SK, Siegel PM, Dankort DL, Webster MA, Muller WJ . (1994). Mammary tumors expressing the neu proto-oncogene possess elevated c-Src tyrosine kinase activity. Mol Cell Biol 14: 735–743.
Nguyen DH, Hussaini IM, Gonias SL . (1998). Binding of urokinase-type plasminogen activator to its receptor in MCF-7 cells activates extracellular signal-regulated kinase 1 and 2 which is required for increased cellular motility. J Biol Chem 273: 8502–8507.
Ottenhoff-Kalff AE, Rijksen G, van Beurden EA, Hennipman A, Michels AA, Staal GE . (1992). Characterization of protein tyrosine kinases from human breast cancer: involvement of the c-src oncogene product. Cancer Res 52: 4773–4778.
Parsons JT, Martin KH, Slack JK, Taylor JM, Weed SA . (2000). Focal adhesion kinase: a regulator of focal adhesion dynamics and cell movement. Oncogene 19: 5606–5613.
Reuter CW, Catling AD, Weber MJ . (1995). Immune complex kinase assays for mitogen-activated protein kinase and MEK. Methods Enzymol 255: 245–256.
Riese II DJ, van Raaij TM, Plowman GD, Andrews GC, Stern DF . (1995). The cellular response to neuregulins is governed by complex interactions of the erbB receptor family. Mol Cell Biol 15: 5770–5776.
Schulze WX, Deng L, Mann M . (2005). Phosphotyrosine interactome of the ErbB-receptor kinase family. Mol Syst Biol 1: 2005–2008.
Sheffield LG . (1998). C-Src activation by ErbB2 leads to attachment-independent growth of human breast epithelial cells. Biochem Biophys Res Commun 250: 27–31.
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL . (1987). Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177–182.
Tan M, Li P, Klos KS, Lu J, Lan KH, Nagata Y et al. (2005). ErbB2 promotes Src synthesis and stability: novel mechanisms of Src activation that confer breast cancer metastasis. Cancer Res 65: 1858–1867.
Tzahar E, Waterman H, Chen X, Levkowitz G, Karunagaran D, Lavi S et al. (1996). A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol 16: 5276–5287.
Wallasch C, Weiss FU, Niederfellner G, Jallal B, Issing W, Ullrich A . (1995). Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3. EMBO J 14: 4267–4275.
Waterman H, Alroy I, Strano S, Seger R, Yarden Y . (1999). The C-terminus of the kinase-defective neuregulin receptor ErbB-3 confers mitogenic superiority and dictates endocytic routing. EMBO J 18: 3348–3358.
Xu W, Doshi A, Lei M, Eck MJ, Harrison SC . (1999). Crystal structures of c-Src reveal features of its autoinhibitory mechanism. Mol Cell 3: 629–638.
Yarden Y, Sliwkowski MX . (2001). Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2: 127–137.
Acknowledgements
We thank S Gonias, K Thomas and J Slack-Davis for technical assistance with the motility assay, as well as C Silva and members of the Parsons-Weber-Parsons group for critical evaluation of this work. We also thank J Hoberg for editorial assistance. This work was supported by a DOD grant DAMD 17-00-1-0487 (RCI) and a NIH-NCI grant CA 71449 (SJP).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ishizawar, R., Miyake, T. & Parsons, S. c-Src modulates ErbB2 and ErbB3 heterocomplex formation and function. Oncogene 26, 3503–3510 (2007). https://doi.org/10.1038/sj.onc.1210138
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1210138
Keywords
This article is cited by
-
SRC kinase-mediated signaling pathways and targeted therapies in breast cancer
Breast Cancer Research (2022)
-
Met–HER3 crosstalk supports proliferation via MPZL3 in MET-amplified cancer cells
Cellular and Molecular Life Sciences (2022)
-
Heregulin-induced cell migration is prevented by trastuzumab and trastuzumab-emtansine in HER2+ breast cancer
Breast Cancer Research and Treatment (2021)
-
Electrotaxis of Glioblastoma and Medulloblastoma Spheroidal Aggregates
Scientific Reports (2019)
-
Posttranscriptional upregulation of HER3 by HER2 mRNA induces trastuzumab resistance in breast cancer
Molecular Cancer (2018)